Side-by-side comparison of AI visibility scores, market position, and capabilities
Dearborn MI automaker (NYSE: F) at $185B 2024 revenue (+5%); F-150 #1 US truck 40+ years, Ford Pro $7.4B op profit (9 months), EV losses ongoing, $2B aluminum supply disruption competing with GM and Tesla.
Ford Motor Company is a Dearborn, Michigan-based American automaker — publicly traded on the New York Stock Exchange (NYSE: F) as an S&P 500 Consumer Discretionary component — designing, manufacturing, marketing, and financing a full range of passenger cars, trucks, and commercial vehicles under the Ford and Lincoln brands through approximately 177,000 employees worldwide. In fiscal year 2024, Ford reported annual revenue of $185 billion (+5% from 2023) and net income of $5.88 billion, with Ford Pro (the commercial vehicle division serving fleet operators, government agencies, and small businesses with F-150, Super Duty F-250/F-350/F-450, and Transit vans) generating $7.4 billion in operating profit in the first nine months alone — making Ford Pro the company's most profitable and fastest-growing business. The F-150 pickup truck remains the best-selling vehicle in the United States for more than 40 consecutive years, generating the revenue foundation that finances Ford's EV and technology investments. CEO Jim Farley's "Ford+" strategy organizes the company into three segments: Ford Blue (profitable ICE vehicle business — Bronco, Explorer, Ranger, Maverick, F-150), Ford Pro (commercial vehicles — market leadership in commercial trucks and work vans), and Ford Model e (EV program — F-150 Lightning, Mustang Mach-E, future EV products). Ford Model e accumulated approximately $5 billion in operating losses in 2023 as battery costs, pricing competition from Tesla, and slower-than-expected EV adoption compressed EV margins. A supply chain challenge in 2024-2025 — an aluminum supply disruption expected to cost up to $2 billion in EBIT — highlights Ford's exposure to raw material and trade policy risks as aluminum tariff policy creates supplier volatility.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.